Posted: Monday, May 22, 2023
For patients with prostate cancer who are receiving androgen-deprivation therapy, the out-of-pocket cost of treatment as well as the route of administration of treatment may be among the most important attributes considered, according to a presentation given at the American Urological Association (AUA) Annual Meeting 2023 (Abstract MP11-03) and published in The Journal of Urology. Thus, shared decision-making between physicians and patients to provide individualized care is indicated in this patient population, according to Sean P. Collins, MD, PhD, of MedStar Georgetown University Hospital, Washington, DC, and colleagues.
A total of 304 men with self-reported prostate cancer were recruited for the study. All patients had at least 3 years of health-care coverage before enrollment and were at least 40 years old. A total of 49% of patients had received previous androgen-deprivation therapy. All men were required to complete surveys that assessed their satisfaction with the treatment and its various attributes.
The study revealed that the two most important attributes of androgen-deprivation therapy that mattered to these patients included decreasing the out-of-pocket cost (from $350 to $5 per month) and modifying the route of administration from monthly injections to daily oral dosing. Additional important attributes of treatment included improved sexual activity, a reduced time to recovery after discontinuing treatment, a decreased risk of cardiovascular events, and a surge of testosterone after initializing treatment. Moreover, non-White men, men with cardiovascular disease, and patients with prostate cancer metastases valued the daily-dosing modification the most. Furthermore, no significant differences in relative importance were identified between patients who previously received androgen-deprivation therapy and those who did not.
Disclosure: No disclosure information was provided.